Teva Pharmaceutical Industries seeks further growth

Teva Pharmaceutical Industries’ $40.5bn (€36.2bn) purchase of Allergan’s generics unit, which has formally been completed, doesn’t signal that the Israeli drugmaker will let up its quest for innovative branded medicines.
Teva Pharmaceutical Industries seeks further growth

Efforts to introduce new copycat drugs and integrate operations gained through its largest acquisition “doesn’t mean we confine our business to just generics,” chief executive Erez Vigodman said in an interview at Teva’s headquarters in Petach Tikva in Israel.

“The strategy and vision are much broader.”

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited